Showing results (411-420 of 504) with videos related to
Sort By:
Pageof 51
British Journal of Haematology|December 29, 2007
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphomaAndrew M Evens, Jane N Winter, Nanjiang Hou, et al.Regulatory Toxicology and Pharmacology : RTP|September 25, 2023
Harmonisation of read-across methodology for drug substance extractables and leachables (E&Ls)Melisa Masuda-Herrera, Hannah T Rosen, Anders Burild, et al.American Journal of Clinical Pathology|July 17, 2008
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- diseaseKatalin Kelemen, Loann C Peterson, Irene Helenowski, et al.Journal of Hematology & Oncology|April 27, 2021
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosineRalf Buettner, Le Xuan Truong Nguyen, Corey Morales, et al.Cancers|November 27, 2021
Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis FungoidesCosimo Di Raimondo, Zhen Han, Chingyu Su, et al.Leukemia & Lymphoma|April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomesOlga Frankfurt, Shuo Ma, Leo Gordon, et al.Oncotarget|October 8, 2016
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphomaAtish Mohanty, Natalie Sandoval, Manasi Das, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Novel antineoplastic agents with efficacy against multidrug resistant tumor cellsJ C Medina, B Shan, H Beckmann, et al.JCI Insight|July 10, 2023
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphomaZhen Han, Xiwei Wu, Hanjun Qin, et al.Journal for Immunotherapy of Cancer|March 23, 2021
Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancerXu Cao, Bolei Li, Jing Chen, et al.Pageof 51